Epcoritamab (EPKINLY®) FDA Approved for Patients with Relapsed or Refractory Follicular Lymphoma

Epcoritamab (EPKINLY®) FDA Approved for Patients with Relapsed or Refractory Follicular Lymphoma

By, Admin 28 June 2024

Overview

Genmab A/S (Nasdaq: GMAB) has received approval from the U.S. Food and Drug Administration (FDA) for EPKINLY® (epcoritamab-bysp) to treat adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more prior systemic therapies. This marks EPKINLY as the first subcutaneously administered T-cell engaging bispecific antibody approved in the U.S. for this patient group under accelerated approval based on response rates. Continued approval will hinge on further verification of clinical benefits in subsequent trials.

Follicular Lymphoma

  • Follicular lymphoma, the second most prevalent form of non-Hodgkin’s lymphoma (NHL), affects approximately 15,000 individuals annually in the U.S. 
  • FL is currently incurable with existing treatments, often leading to relapses and shorter response durations with each successive treatment regimen.

1/2 EPCORE® NHL-1 Trial: Behind FDA  Approval

  • The FDA's decision is supported by data from the phase 1/2 EPCORE® NHL-1 trial involving 127 adults with R/R FL. 
  • Results demonstrated an overall response rate (ORR) of 82%, with 60% achieving complete response (CR) and 67% achieving minimal residual disease negativity. 
  • Notably, responses were durable, with over half of responders maintaining their response at a median follow-up of 14.8 months.

Adverse Events

  • Common treatment-related adverse events (AEs) included injection site reactions, cytokine release syndrome (CRS), fatigue, and infections. 
  • CRS, managed through a step-up dosing regimen, was primarily low-grade, with no grade 3 events observed.

EPKINLY Approval

  • The approval of EPKINLY expands the treatment options available for patients with challenging FL cases, offering potential benefits without requiring hospitalization. 
  • Ongoing trials are assessing EPKINLY’s efficacy across various hematologic malignancies.

Warnings

In terms of safety, EPKINLY carries warnings for serious CRS, immune effector cell-associated neurotoxicity syndrome (ICANS), infections, cytopenias, and embryo-fetal toxicity.

Co-developers of EPKINLY

Genmab and AbbVie, co-developers of EPKINLY, continue to explore its potential in monotherapy and combination therapies across different types of lymphoma.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!